Advertisement

Topics

AVROBIO Company Profile

03:01 EDT 20th June 2019 | BioPortfolio

AVROBIO is a clinical stage company developing transformative ex-vivo gene therapies targeting cancer and rare diseases. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to treat serious debilitating disease resulting in durable patient outcomes. A unifying theme across our portfolio is the expert design and manufacturing of optimal cell and gene delivery systems. AVROBIO has offices in both Toronto, ON and Cambridge, MA. More information is available at www.avrobio.com.


News Articles [26 Associated News Articles listed on BioPortfolio]

Avrobio's cystinosis candidate accepted by FDA

The FDA has accepted Avrobio's investigational new drug application for AVR-RD-04, which is indicated for the treatment of pa -More- 

Today, AVROBIO welcomes newly appointed senior management leaders. http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-expands-and-strengthens-leadership-team-four-senior …

Today, AVROBIO welcomes newly appointed senior management leaders. http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-expands-and-strengthens-leadership-team-four-senior ...

Avrobio to incorporate plato platform into FAB-201 Phase II trial

Avrobio is set to incorporate its plato platform into its FAB-201 Phase II trial and dose patients at clinical sites...Read More... The post Avrobio to incorporate plato platform into FAB-201 Phase II...

AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39th ...

AVROBIO Announces Acceptance of Investigational New Drug (IND) Application

AVROBIO (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared to begin a Phase 1/2 clinic...

Nerissa Kreher Leaves Avrobio for Tiburio Chief Medical Officer Post

Tiburio Therapeutics has appointed Nerissa Kreher to the newly created position of chief medical officer. Kreher held that post at her previous company, Avrobio (NASDAQ: AVRO). Her experience also inc...

AVROBIO, Inc. Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company,  today announced that the Company has been sele...

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

AVROBIO

AVROBIO is a clinical stage company developing transformative ex-vivo gene therapies targeting cancer and rare diseases. The catalyst for creating AVROBIO is to accelerate scienti...

AVROBIO, Inc.

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives w...

More Information about "AVROBIO" on BioPortfolio

We have published hundreds of AVROBIO news stories on BioPortfolio along with dozens of AVROBIO Clinical Trials and PubMed Articles about AVROBIO for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AVROBIO Companies in our database. You can also find out about relevant AVROBIO Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record